Digest Network Come funziona
Network
/
Società
No
Non verificato

Novartis Pharma AG

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

110 comunicati stampa

Guarda tutti i comunicati
20/07/2026
Farmaceutica
Management/Organizzazione Aziendale
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
16/07/2026
Farmaceutica
Annunci Economici
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
05/07/2026
Farmaceutica
Annunci Economici
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
01/07/2026
Farmaceutica
Annunci Economici
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
12/06/2026
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
10/06/2026
Farmaceutica
Annunci Economici
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
08/06/2026
Farmaceutica
Annunci Economici
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
04/06/2026
Farmaceutica
Annunci Economici
Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
03/06/2026
Farmaceutica
Annunci Economici
Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
01/06/2026
Farmaceutica
Annunci Economici
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0